Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of colorectal cancer in patients with Enterococcus faecalis blood stream infection: A nationwide study.

The Journal of infection·2025
Same author

Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.

Journal of hepatology·2025
Same author

Author's reply: "Staging the pre-procedural prophylaxis in decompensated cirrhosis".

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2022
Same author

Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2022
Same author

Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis?

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2021
Same author

Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2021
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Hypercoagulability in cirrhosis: causes and consequences.

A Tripodi1, Q M Anstee, K K Sogaard

  • 1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation and Università degli Studi di Milan, Milan, Italy. armando.tripodi@unimi.it

Journal of Thrombosis and Haemostasis : JTH
|July 7, 2011
PubMed
Summary
This summary is machine-generated.

Cirrhosis may not cause bleeding due to low clotting factors but rather increased thrombin generation. This suggests a potential role for anticoagulation in managing thrombosis and liver fibrosis in these patients.

More Related Videos

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: May 31, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Area of Science:

  • Hepatology
  • Hematology
  • Thrombosis Research

Background:

  • Cirrhosis traditionally viewed as a bleeding disorder due to coagulopathy.
  • Recent evidence suggests normal or increased thrombin generation in cirrhosis patients.
  • Bleeding in cirrhosis may stem from superimposed conditions, not just factor deficiencies.

Purpose of the Study:

  • To re-evaluate the hemostatic balance in cirrhosis.
  • To explore the clinical implications of a procoagulant imbalance in cirrhosis.
  • To investigate the potential benefits of anticoagulation in cirrhosis management.

Main Methods:

  • Review of existing evidence on coagulation abnormalities in cirrhosis.
  • Analysis of the procoagulant imbalance (elevated Factor VIII, decreased Protein C).
  • Discussion of potential clinical consequences and therapeutic implications.

Main Results:

  • Cirrhosis exhibits a procoagulant imbalance, characterized by resistance to thrombomodulin's anticoagulant action.
  • This in vitro hypercoagulability may contribute to venous thromboembolism and portal vein thrombosis.
  • The imbalance might also play a role in liver fibrosis progression.

Conclusions:

  • Cirrhosis may be associated with an increased risk of thrombosis.
  • Anticoagulation could be a viable therapeutic option for select cirrhosis patients.
  • Further clinical studies are needed to confirm the efficacy of anticoagulation in cirrhosis.